14 Most Undervalued NASDAQ Stocks to Buy Now

Page 11 of 14

4. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Forward P/E Ratio as of September 20: 14.73

Number of Hedge Fund Holders: 73

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the most undervalued NASDAQ stocks to buy now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported on September 17 that its experimental medicine garetosmab has met the primary endpoint in a phase 3 trial for adults with fibrodysplasia ossificans progressiva, a rare genetic condition in which muscles, tendons, and ligaments gradually convert into bone.

According to the OPTIMA trial, at 56 weeks, both garetosmab dosages decreased new bone lesions by 90% or more when compared to a placebo.

An Independent Data Monitoring Committee advised switching placebo patients to garetosmab medication immediately based on the safety profile and results. By the end of 2025, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) aims to submit the medication for regulatory approval in the US, with global submissions expected for the year after.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a prominent biopharmaceutical company that discovers, develops, and commercializes medicines for a variety of diseases, including cancer, eye disorders, and allergies.

Page 11 of 14